[
  {
    "title": "康泰生物(300601.SZ)：民海生物的麻腮风联合减毒活疫苗获批临床试验",
    "href": "http://stock.jrj.com.cn/2023/01/05192937262211.shtml",
    "datetime": "2023-01-05 19:29:59",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)截至12月底已累计回购66.04万股",
    "href": "http://stock.jrj.com.cn/2023/01/03193837256326.shtml",
    "datetime": "2023-01-03 19:38:18",
    "code": "300601"
  },
  {
    "title": "康泰生物一致行动人杜兴连拟减持100万股 过去2年多股价已经跌去3/4",
    "href": "http://stock.jrj.com.cn/2022/12/22103237230590.shtml",
    "datetime": "2022-12-22 10:32:57",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：实控人的一致行动人杜兴连拟减持不超100万股",
    "href": "http://stock.jrj.com.cn/2022/12/21205937229563.shtml",
    "datetime": "2022-12-21 20:59:16",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：截至11月底已累计回购66.04万股",
    "href": "http://stock.jrj.com.cn/2022/12/01200037182598.shtml",
    "datetime": "2022-12-01 20:00:42",
    "code": "300601"
  },
  {
    "title": "康泰生物：收到Sabin株脊髓灰质炎灭活疫苗（Vero细胞）Ⅲ期临床试验总结报告",
    "href": "http://stock.jrj.com.cn/2022/11/22174737158027.shtml",
    "datetime": "2022-11-22 17:47:10",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：收到Sabin株脊髓灰质炎灭活疫苗(Vero细胞)Ⅲ期临床试验总结报告",
    "href": "http://stock.jrj.com.cn/2022/11/22174337158054.shtml",
    "datetime": "2022-11-22 17:43:22",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司新冠疫苗Ⅲ期临床试验获得关键性数据",
    "href": "http://stock.jrj.com.cn/2022/11/18193937151105.shtml",
    "datetime": "2022-11-18 19:39:20",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：新冠病毒灭活疫苗(Vero细胞)Ⅲ期临床试验获得关键性数据",
    "href": "http://stock.jrj.com.cn/2022/11/18193737151116.shtml",
    "datetime": "2022-11-18 19:37:42",
    "code": "300601"
  },
  {
    "title": "康泰生物：新冠疫苗Ⅲ期临床试验获得关键性数据",
    "href": "http://stock.jrj.com.cn/2022/11/18193437151100.shtml",
    "datetime": "2022-11-18 19:34:08",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)截至10月底已累计回购66.04万股",
    "href": "http://stock.jrj.com.cn/2022/11/01195037104474.shtml",
    "datetime": "2022-11-01 19:50:21",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：实控人将积极履行员工增持倡议书中作出的承诺",
    "href": "http://stock.jrj.com.cn/2022/11/01194837104437.shtml",
    "datetime": "2022-11-01 19:48:23",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)麻腮风联合减毒活疫苗临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/10/16220237058758.shtml",
    "datetime": "2022-10-16 22:02:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：截至9月底累计耗资1999.36万元回购66.04万股",
    "href": "http://stock.jrj.com.cn/2022/10/11175837047635.shtml",
    "datetime": "2022-10-11 17:58:03",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：9月26日起“康泰转2”恢复转股",
    "href": "http://stock.jrj.com.cn/2022/09/23202037018362.shtml",
    "datetime": "2022-09-23 20:20:15",
    "code": "300601"
  },
  {
    "title": "康泰生物：子公司民海生物水痘减毒活疫苗申请生产注册获得受理",
    "href": "http://stock.jrj.com.cn/2022/09/15152236997165.shtml",
    "datetime": "2022-09-15 15:22:06",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：“康泰转2”的转股价下修为33.66元/股、明起生效",
    "href": "http://stock.jrj.com.cn/2022/09/14205936995344.shtml",
    "datetime": "2022-09-14 20:59:34",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：水痘减毒活疫苗申请生产注册获得受理",
    "href": "http://stock.jrj.com.cn/2022/09/14205736995346.shtml",
    "datetime": "2022-09-14 20:57:49",
    "code": "300601"
  },
  {
    "title": "康泰生物：水痘减毒活疫苗申请生产注册获得受理",
    "href": "http://stock.jrj.com.cn/2022/09/14205436995334.shtml",
    "datetime": "2022-09-14 20:54:34",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：四价流感病毒裂解疫苗获批临床",
    "href": "http://stock.jrj.com.cn/2022/08/24181436931379.shtml",
    "datetime": "2022-08-24 18:14:08",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：董事会提议向下修正可转债的转股价",
    "href": "http://stock.jrj.com.cn/2022/08/18220136913919.shtml",
    "datetime": "2022-08-18 22:01:40",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：拟滚动使用不超30亿元自有资金购买理财产品",
    "href": "http://stock.jrj.com.cn/2022/08/18215936913897.shtml",
    "datetime": "2022-08-18 21:59:48",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：拟变更部分募集资金用途、6.6亿元永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2022/08/18215736913901.shtml",
    "datetime": "2022-08-18 21:57:41",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：拟以1亿元-2亿元回购公司股份",
    "href": "http://stock.jrj.com.cn/2022/08/18215536913904.shtml",
    "datetime": "2022-08-18 21:55:25",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)半年度净利润1.21亿元 同比下降64.19%",
    "href": "http://stock.jrj.com.cn/2022/08/18174636912660.shtml",
    "datetime": "2022-08-18 17:46:37",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟以1亿元-2亿元回购股份",
    "href": "http://stock.jrj.com.cn/2022/08/18174536912578.shtml",
    "datetime": "2022-08-18 17:45:04",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：“康泰转2”预计触发转股价格修正条件",
    "href": "http://stock.jrj.com.cn/2022/08/11214136892304.shtml",
    "datetime": "2022-08-11 21:41:51",
    "code": "300601"
  },
  {
    "title": "新冠疫苗遭遇全球产能过剩？康泰生物Q2净亏仅是前奏？",
    "href": "http://stock.jrj.com.cn/2022/08/03154936866775.shtml",
    "datetime": "2022-08-03 15:49:55",
    "code": "300601"
  },
  {
    "title": "康泰生物：多名董事、高管拟合计增持公司股票不低于4500万元",
    "href": "http://stock.jrj.com.cn/2022/08/01212136860730.shtml",
    "datetime": "2022-08-01 21:21:59",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：董事长杜伟民、总裁苗向等若干董高拟合计增持不低于4500万元公司股份",
    "href": "http://stock.jrj.com.cn/2022/08/01211636860716.shtml",
    "datetime": "2022-08-01 21:16:51",
    "code": "300601"
  },
  {
    "title": "康泰生物新冠疫苗红利不再单季预亏1.7亿 市值缩水1200亿年内76家基金清仓撤离",
    "href": "http://stock.jrj.com.cn/2022/07/26101636842758.shtml",
    "datetime": "2022-07-26 10:16:20",
    "code": "300601"
  },
  {
    "title": "新冠疫苗市场红利降温 康泰生物中报净利预降近七成",
    "href": "http://stock.jrj.com.cn/2022/07/26090736842540.shtml",
    "datetime": "2022-07-26 09:07:47",
    "code": "300601"
  },
  {
    "title": "六成净利同比“蒸发”，康泰生物“命悬一苗”",
    "href": "http://stock.jrj.com.cn/2022/07/25204236841249.shtml",
    "datetime": "2022-07-25 20:42:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：预计2022年半年度盈利1亿至1.3亿元，净利润同比下降70.29%至61.37%",
    "href": "http://stock.jrj.com.cn/2022/07/25112536839397.shtml",
    "datetime": "2022-07-25 11:25:50",
    "code": "300601"
  },
  {
    "title": "上半年净利预降61%至70% 康泰生物开盘跌6.31%",
    "href": "http://stock.jrj.com.cn/2022/07/25094436838982.shtml",
    "datetime": "2022-07-25 09:44:28",
    "code": "300601"
  },
  {
    "title": "400亿新冠疫苗龙头业绩“爆雷”！",
    "href": "http://stock.jrj.com.cn/2022/07/25001036838322.shtml",
    "datetime": "2022-07-25 00:10:35",
    "code": "300601"
  },
  {
    "title": "震惊！这国顶级大学突发惨案，什么情况？420亿巨头突现黑天鹅，“猪吃猪”现象刷屏，中东连起两场大火",
    "href": "http://stock.jrj.com.cn/2022/07/25000736838321.shtml",
    "datetime": "2022-07-25 00:07:25",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司四价流感病毒裂解疫苗临床试验申请已获得国家药品监督管理局的受理",
    "href": "http://stock.jrj.com.cn/2022/06/28113636763715.shtml",
    "datetime": "2022-06-28 11:36:46",
    "code": "300601"
  },
  {
    "title": "康泰生物：四价流感病毒裂解疫苗临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/06/27184336762059.shtml",
    "datetime": "2022-06-27 18:43:36",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)2021年度权益分派10转6派8.5元 股权登记日为6月1日",
    "href": "http://stock.jrj.com.cn/2022/05/26223136682760.shtml",
    "datetime": "2022-05-26 22:31:18",
    "code": "300601"
  },
  {
    "title": "又暴跌了！康泰生物蒸发1300亿，“疫苗大王”杜伟民遭股民怒问",
    "href": "http://stock.jrj.com.cn/2022/05/17184836656057.shtml",
    "datetime": "2022-05-17 18:48:30",
    "code": "300601"
  },
  {
    "title": "A股异动 | 康泰生物(300601.SZ)大跌超15% 控股股东524.11万股将被司法拍卖",
    "href": "http://stock.jrj.com.cn/2022/05/17135936654743.shtml",
    "datetime": "2022-05-17 13:59:32",
    "code": "300601"
  },
  {
    "title": "康泰生物：控股股东杜伟民所持524.11万股将被司法拍卖",
    "href": "http://stock.jrj.com.cn/2022/05/17103536654273.shtml",
    "datetime": "2022-05-17 10:35:58",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：控股股东所持524.11万股将被司法拍卖",
    "href": "http://stock.jrj.com.cn/2022/05/17082436653752.shtml",
    "datetime": "2022-05-17 08:24:55",
    "code": "300601"
  },
  {
    "title": "康泰生物：业绩虚胖有玄机",
    "href": "http://stock.jrj.com.cn/2022/05/11151136633139.shtml",
    "datetime": "2022-05-11 15:11:45",
    "code": "300601"
  },
  {
    "title": "康泰生物2022年第一季度净利2.74亿同比增长987.71% 销售收入增加",
    "href": "http://stock.jrj.com.cn/2022/05/04211136559844.shtml",
    "datetime": "2022-05-04 21:11:42",
    "code": "300601"
  },
  {
    "title": "康泰生物2021年净利12.63亿同比增长86.01% 董事长杜伟民薪酬239.22万",
    "href": "http://stock.jrj.com.cn/2022/04/29105036501940.shtml",
    "datetime": "2022-04-29 10:50:44",
    "code": "300601"
  },
  {
    "title": "康泰生物：2022年第一季度归母净利润增长近10倍",
    "href": "http://stock.jrj.com.cn/2022/04/28141336492168.shtml",
    "datetime": "2022-04-28 14:13:57",
    "code": "300601"
  },
  {
    "title": "【晚间公告全知道】ST国医下属医院收到西安市卫生健康委员会复诊通知、康泰生物预计一季度净利同比增1093%",
    "href": "http://stock.jrj.com.cn/2022/04/13213336327476.shtml",
    "datetime": "2022-04-13 21:33:29",
    "code": "300601"
  },
  {
    "title": "康泰生物：2022年第一季度，归母净利润至多同比增超10倍",
    "href": "http://stock.jrj.com.cn/2022/04/13195836326512.shtml",
    "datetime": "2022-04-13 19:58:40",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)业绩快报：2021年度净利升89.06%至12.84亿元",
    "href": "http://stock.jrj.com.cn/2022/04/13190336325993.shtml",
    "datetime": "2022-04-13 19:03:04",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：一季度扣非净利润预增2483.83%-3060.38%",
    "href": "http://stock.jrj.com.cn/2022/04/13185936325952.shtml",
    "datetime": "2022-04-13 18:59:53",
    "code": "300601"
  },
  {
    "title": "康泰生物：预计一季度净利同比增长893.93%-1092.72%",
    "href": "http://stock.jrj.com.cn/2022/04/13185736325951.shtml",
    "datetime": "2022-04-13 18:57:45",
    "code": "300601"
  },
  {
    "title": "A股异动 | 康泰生物(300601.SZ)大涨逾7% 冻干水痘减毒活疫苗临床研究阶段工作顺利完成",
    "href": "http://stock.jrj.com.cn/2022/03/24144534895931.shtml",
    "datetime": "2022-03-24 14:45:10",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：冻干水痘减毒活疫苗临床研究阶段工作顺利完成",
    "href": "http://stock.jrj.com.cn/2022/03/23162234867728.shtml",
    "datetime": "2022-03-23 16:22:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：无细胞百白破b型流感嗜血杆菌联合疫苗获批再注册",
    "href": "http://stock.jrj.com.cn/2022/03/16181534835159.shtml",
    "datetime": "2022-03-16 18:15:42",
    "code": "300601"
  },
  {
    "title": "康泰生物2021年预计12亿-14亿 同比增长77%-106% 公司产品销量稳步提升",
    "href": "http://stock.jrj.com.cn/2022/01/28221034251100.shtml",
    "datetime": "2022-01-28 22:10:49",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)2021年度净利润预增76.68%-106.13%",
    "href": "http://stock.jrj.com.cn/2022/01/28194234246242.shtml",
    "datetime": "2022-01-28 19:42:27",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：CDE启动冻干人用狂犬病疫苗(人二倍体细胞)注册现场核查",
    "href": "http://stock.jrj.com.cn/2022/01/23174734194514.shtml",
    "datetime": "2022-01-23 17:47:12",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：“康泰转2”自1月21日起开始转股",
    "href": "http://stock.jrj.com.cn/2022/01/19203434175487.shtml",
    "datetime": "2022-01-19 20:34:31",
    "code": "300601"
  },
  {
    "title": "康泰生物跌6.69% 申银万国东吴证券去年高点喊买入",
    "href": "http://stock.jrj.com.cn/2022/01/05170634123791.shtml",
    "datetime": "2022-01-05 17:06:00",
    "code": "300601"
  },
  {
    "title": "康泰生物跌4.06% 申银万国东吴证券高点喊买入",
    "href": "http://stock.jrj.com.cn/2021/12/17175234031894.shtml",
    "datetime": "2021-12-17 17:52:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：子公司民海生物通过高新技术企业再次认定",
    "href": "http://stock.jrj.com.cn/2021/11/29175633938716.shtml",
    "datetime": "2021-11-29 17:56:14",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：口服五价重配轮状病毒减毒活疫苗(Vero细胞)获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/17195933867637.shtml",
    "datetime": "2021-11-17 19:59:59",
    "code": "300601"
  },
  {
    "title": "康泰生物口服五价重配轮状病毒减毒活疫苗（Vero细胞）临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/11/17195533867632.shtml",
    "datetime": "2021-11-17 19:55:18",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获受理",
    "href": "http://stock.jrj.com.cn/2021/11/08163733823464.shtml",
    "datetime": "2021-11-08 16:37:54",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：兜底增持号召已获126名员工响应 累计增持37.37万股",
    "href": "http://stock.jrj.com.cn/2021/11/02114933802675.shtml",
    "datetime": "2021-11-02 11:49:12",
    "code": "300601"
  },
  {
    "title": "康泰生物前三季净利润大增139% 研发投入“节节攀升”",
    "href": "http://stock.jrj.com.cn/2021/10/25084133745530.shtml",
    "datetime": "2021-10-25 08:41:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：无细胞百白破b型流感嗜血杆菌联合疫苗获乌兹别克斯坦药品再注册证书",
    "href": "http://stock.jrj.com.cn/2021/10/22195433735156.shtml",
    "datetime": "2021-10-22 19:54:58",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：13价肺炎球菌多糖结合疫苗首批产品获得批签发证明",
    "href": "http://stock.jrj.com.cn/2021/10/22195333735153.shtml",
    "datetime": "2021-10-22 19:53:18",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)拉升涨近8% 三季度净利润暴增303.21%",
    "href": "http://stock.jrj.com.cn/2021/10/22104133731865.shtml",
    "datetime": "2021-10-22 10:41:48",
    "code": "300601"
  },
  {
    "title": "康泰生物2021年前三季度净利10.36亿元 同比净利增加139.13%",
    "href": "http://stock.jrj.com.cn/2021/10/21170433727793.shtml",
    "datetime": "2021-10-21 17:04:10",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：第三季度净利升303.21%至7.00亿元",
    "href": "http://stock.jrj.com.cn/2021/10/21170333727702.shtml",
    "datetime": "2021-10-21 17:03:17",
    "code": "300601"
  },
  {
    "title": "增持倡议遭交易所问询后 康泰生物二股东减持计划提前“刹车”",
    "href": "http://stock.jrj.com.cn/2021/09/30090533540981.shtml",
    "datetime": "2021-09-30 09:05:44",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：股东YUAN LI PING承诺6个月内不减持",
    "href": "http://stock.jrj.com.cn/2021/09/28183633531734.shtml",
    "datetime": "2021-09-28 18:36:02",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)半年度权益分派10派3元 股权登记日为9月28日",
    "href": "http://stock.jrj.com.cn/2021/09/23215633506810.shtml",
    "datetime": "2021-09-23 21:56:49",
    "code": "300601"
  },
  {
    "title": "康泰生物实控人与外籍前妻减持 倡议员工增持收关注函",
    "href": "http://stock.jrj.com.cn/2021/09/23172533505240.shtml",
    "datetime": "2021-09-23 17:25:00",
    "code": "300601"
  },
  {
    "title": "康泰生物收函：实控人鼓励员工增持，自己却先套现逾9千万？",
    "href": "http://stock.jrj.com.cn/2021/09/23103133503513.shtml",
    "datetime": "2021-09-23 10:31:08",
    "code": "300601"
  },
  {
    "title": "康泰生物：控股股东、实控人杜伟民向公司员工发出增持公司股票倡议书",
    "href": "http://stock.jrj.com.cn/2021/09/17135033450878.shtml",
    "datetime": "2021-09-17 13:50:55",
    "code": "300601"
  },
  {
    "title": "康泰生物股价异动拉升冲击涨停，公司实控人倡议员工增持并承诺兜底",
    "href": "http://stock.jrj.com.cn/2021/09/17130733450553.shtml",
    "datetime": "2021-09-17 13:07:54",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)直线拉升 实控人倡议员工增持公司股票",
    "href": "http://stock.jrj.com.cn/2021/09/17130733450554.shtml",
    "datetime": "2021-09-17 13:07:01",
    "code": "300601"
  },
  {
    "title": "康泰生物：控股股东、实控人向公司员工发出增持公司股票倡议书 承诺兜底",
    "href": "http://stock.jrj.com.cn/2021/09/17115933450377.shtml",
    "datetime": "2021-09-17 11:59:42",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：控股股东、实控人发“兜底”增持倡议",
    "href": "http://stock.jrj.com.cn/2021/09/17114933450365.shtml",
    "datetime": "2021-09-17 11:49:54",
    "code": "300601"
  },
  {
    "title": "卓胜微、康泰生物跌超5%，双创基金ETF（159783）跌幅扩大",
    "href": "http://stock.jrj.com.cn/2021/09/15140233439062.shtml",
    "datetime": "2021-09-15 14:02:32",
    "code": "300601"
  },
  {
    "title": "康泰生物、沃森生物、乐普医疗跌超4%，科创创业ETF（588360）跌超1%",
    "href": "http://stock.jrj.com.cn/2021/09/15134133438992.shtml",
    "datetime": "2021-09-15 13:41:19",
    "code": "300601"
  },
  {
    "title": "康泰生物股东杜伟民减持51.6万股 套现9331.34万 上半年公司净利3.37亿",
    "href": "http://stock.jrj.com.cn/2021/09/10220633417273.shtml",
    "datetime": "2021-09-10 22:06:06",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：实控人杜伟民已通过集中竞价减持51.6万股",
    "href": "http://stock.jrj.com.cn/2021/09/10195633416737.shtml",
    "datetime": "2021-09-10 19:56:11",
    "code": "300601"
  },
  {
    "title": "康泰生物跌7.24% 申银万国东吴证券高点喊买入",
    "href": "http://stock.jrj.com.cn/2021/09/10173233415953.shtml",
    "datetime": "2021-09-10 17:32:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：13价肺炎球菌多糖结合疫苗获得药品注册证书 将进一步丰富公司产品梯队",
    "href": "http://stock.jrj.com.cn/2021/09/10111433414178.shtml",
    "datetime": "2021-09-10 11:14:37",
    "code": "300601"
  },
  {
    "title": "康泰生物13 价肺炎球菌多糖结合疫苗获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/09/10101433413720.shtml",
    "datetime": "2021-09-10 10:14:49",
    "code": "300601"
  },
  {
    "title": "康泰生物13价肺炎球菌多糖结合疫苗获药品注册证书 为全球第三家 | 公司要闻",
    "href": "http://stock.jrj.com.cn/2021/09/10092933413380.shtml",
    "datetime": "2021-09-10 09:29:22",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：13价肺炎球菌多糖结合疫苗获批上市",
    "href": "http://stock.jrj.com.cn/2021/09/10082933413124.shtml",
    "datetime": "2021-09-10 08:29:05",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：实控人杜伟民质押139万股及解押400万股",
    "href": "http://stock.jrj.com.cn/2021/09/02203133375775.shtml",
    "datetime": "2021-09-02 20:31:15",
    "code": "300601"
  },
  {
    "title": "康泰生物2021年半年度净利3.37亿元 同比净利增加29.54%",
    "href": "http://stock.jrj.com.cn/2021/08/29201333341514.shtml",
    "datetime": "2021-08-29 20:13:46",
    "code": "300601"
  },
  {
    "title": "康泰生物：上半年净利润3.37亿元 同比增30%",
    "href": "http://stock.jrj.com.cn/2021/08/29174833340884.shtml",
    "datetime": "2021-08-29 17:48:42",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)上半年净利润3.37亿元 同比增长29.54%",
    "href": "http://stock.jrj.com.cn/2021/08/29171933340773.shtml",
    "datetime": "2021-08-29 17:19:50",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：上半年净利增29.54%至3.37亿元",
    "href": "http://stock.jrj.com.cn/2021/08/29170633340724.shtml",
    "datetime": "2021-08-29 17:06:16",
    "code": "300601"
  },
  {
    "title": "康泰生物：上半年净利润3.37亿元 同比增长30%",
    "href": "http://stock.jrj.com.cn/2021/08/29161933340578.shtml",
    "datetime": "2021-08-29 16:19:39",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：272.28万股限制性股票将于8月10日上市流通",
    "href": "http://stock.jrj.com.cn/2021/08/05203333208912.shtml",
    "datetime": "2021-08-05 20:33:08",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)高开8.1% “德尔塔”研发取得重要进展",
    "href": "http://stock.jrj.com.cn/2021/08/05092933205445.shtml",
    "datetime": "2021-08-05 09:29:55",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：约296.57万股限制性股票可解除限售",
    "href": "http://stock.jrj.com.cn/2021/07/29220233171702.shtml",
    "datetime": "2021-07-29 22:02:02",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：拟使用不超15亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/07/29215833171672.shtml",
    "datetime": "2021-07-29 21:58:50",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)披露可转债发行结果：遭弃购14.4901万张 由主承销商包销",
    "href": "http://stock.jrj.com.cn/2021/07/20215233126159.shtml",
    "datetime": "2021-07-20 21:52:36",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)可转债网上中签结果出炉：中签号共130.1816万个",
    "href": "http://stock.jrj.com.cn/2021/07/18170933112573.shtml",
    "datetime": "2021-07-18 17:09:53",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：与嘉晨西海签署mRNA人用传染病疫苗项目战略合作协议",
    "href": "http://stock.jrj.com.cn/2021/07/18170833112572.shtml",
    "datetime": "2021-07-18 17:08:12",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：拟向不特定对象发行20亿元可转债",
    "href": "http://stock.jrj.com.cn/2021/07/12204333084308.shtml",
    "datetime": "2021-07-12 20:43:19",
    "code": "300601"
  },
  {
    "title": "疫苗板块走弱 康泰生物大跌超10%",
    "href": "http://stock.jrj.com.cn/2021/06/15105932933244.shtml",
    "datetime": "2021-06-15 10:59:45",
    "code": "300601"
  },
  {
    "title": "康泰生物：YUAN LIPING拟减持不超1300万股及转让不超700万股予其持100%份额的私募基金产品",
    "href": "http://stock.jrj.com.cn/2021/06/11210032913864.shtml",
    "datetime": "2021-06-11 21:00:25",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：减持期过半 杜伟民减持约52万股",
    "href": "http://stock.jrj.com.cn/2021/06/11205332913836.shtml",
    "datetime": "2021-06-11 20:53:52",
    "code": "300601"
  },
  {
    "title": "康泰生物：经咨询股东 该部分股份由YUAN LI PING女士控制 股份并未卖出",
    "href": "http://stock.jrj.com.cn/2021/06/09121232898922.shtml",
    "datetime": "2021-06-09 12:12:24",
    "code": "300601"
  },
  {
    "title": "康泰生物：康泰新冠疫苗由公司自主研发并在国内已纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2021/06/09114532898784.shtml",
    "datetime": "2021-06-09 11:45:54",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司不存在新一轮股权激励",
    "href": "http://stock.jrj.com.cn/2021/06/09114532898782.shtml",
    "datetime": "2021-06-09 11:45:38",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司疫苗产品有比较好的稳定性但建议开瓶后需尽快进行接种使用",
    "href": "http://stock.jrj.com.cn/2021/06/09114432898755.shtml",
    "datetime": "2021-06-09 11:44:17",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：发行可转债申请获中证监同意注册批复",
    "href": "http://stock.jrj.com.cn/2021/06/08142432893076.shtml",
    "datetime": "2021-06-08 14:24:58",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：冻干b型流感嗜血杆菌结合疫苗获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/08142132893053.shtml",
    "datetime": "2021-06-08 14:21:08",
    "code": "300601"
  },
  {
    "title": "康华生物：康泰生物二倍体狂苗的上市对公司总体影响有限",
    "href": "http://stock.jrj.com.cn/2021/06/08070732890617.shtml",
    "datetime": "2021-06-08 07:07:38",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：128.9631万股限制性股票将解除限售上市流通",
    "href": "http://stock.jrj.com.cn/2021/05/31144132849003.shtml",
    "datetime": "2021-05-31 14:41:55",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：136.275万份股票期权可行权",
    "href": "http://stock.jrj.com.cn/2021/05/26162932823508.shtml",
    "datetime": "2021-05-26 16:29:47",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：实控人杜伟民解押898.474万股",
    "href": "http://stock.jrj.com.cn/2021/05/26160232823364.shtml",
    "datetime": "2021-05-26 16:02:39",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司控股股东、实际控制人部分股份解除质押",
    "href": "http://stock.jrj.com.cn/2021/05/26155132823715.shtml",
    "datetime": "2021-05-26 15:51:23",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：YUAN LI PING已完成减持1700万股",
    "href": "http://stock.jrj.com.cn/2021/05/18211832778187.shtml",
    "datetime": "2021-05-18 21:18:47",
    "code": "300601"
  },
  {
    "title": "康泰生物：研发的新冠灭活疫苗纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2021/05/17103032768097.shtml",
    "datetime": "2021-05-17 10:30:42",
    "code": "300601"
  },
  {
    "title": "A股异动 | 康泰生物(300601.SZ)高开逾7% 新型冠状病毒灭活疫苗纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2021/05/17093232767561.shtml",
    "datetime": "2021-05-17 09:32:12",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：新型冠状病毒灭活疫苗被纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2021/05/14194532756942.shtml",
    "datetime": "2021-05-14 19:45:17",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司自主研发的新型冠状病毒灭活疫苗纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2021/05/14194432756935.shtml",
    "datetime": "2021-05-14 19:44:16",
    "code": "300601"
  },
  {
    "title": "康泰生物：一季度业绩承压 新产品等待获批上市",
    "href": "http://stock.jrj.com.cn/2021/05/13075532746067.shtml",
    "datetime": "2021-05-13 07:55:25",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司自主研发的13价肺炎球菌结合疫苗完成注册现场检查工作",
    "href": "http://stock.jrj.com.cn/2021/05/10140032728696.shtml",
    "datetime": "2021-05-10 14:00:48",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：YUAN LI PING 减持数过半 累计减持1591.45万股",
    "href": "http://stock.jrj.com.cn/2021/05/07215632713637.shtml",
    "datetime": "2021-05-07 21:56:37",
    "code": "300601"
  },
  {
    "title": "A股异动 | 康泰生物(300601.SZ)大涨9% 首季净利同比增超9倍",
    "href": "http://stock.jrj.com.cn/2021/04/30143932486886.shtml",
    "datetime": "2021-04-30 14:39:06",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)一季度净利升937.58%至2515.26万元",
    "href": "http://stock.jrj.com.cn/2021/04/29163932480299.shtml",
    "datetime": "2021-04-29 16:39:27",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)2020年净利升18.22%至6.79亿元",
    "href": "http://stock.jrj.com.cn/2021/04/29163632480281.shtml",
    "datetime": "2021-04-29 16:36:30",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司冻干人用狂犬病疫苗（人二倍体细胞）车间已完成建设并已有试生产",
    "href": "http://stock.jrj.com.cn/2021/04/12131832357180.shtml",
    "datetime": "2021-04-12 13:18:02",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司与阿斯利康的合作方式为技术引进而非代工生产",
    "href": "http://stock.jrj.com.cn/2021/04/12130532357092.shtml",
    "datetime": "2021-04-12 13:05:06",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司Hib原液既可以做Hib疫苗又可以做四联苗",
    "href": "http://stock.jrj.com.cn/2021/04/12130432357083.shtml",
    "datetime": "2021-04-12 13:04:31",
    "code": "300601"
  },
  {
    "title": "康泰生物：目前公司已基本完成省级招标准入工作",
    "href": "http://stock.jrj.com.cn/2021/04/12130332357086.shtml",
    "datetime": "2021-04-12 13:03:58",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司13价肺炎球菌多糖结合疫苗生产现场检查工作结束后 还需获得药品注册批件后方能组织生产",
    "href": "http://stock.jrj.com.cn/2021/04/12120432356887.shtml",
    "datetime": "2021-04-12 12:04:37",
    "code": "300601"
  },
  {
    "title": "A股异动 | 康泰生物(300601.SZ)涨近5% P3生物安全生产车间已完成建设并已通过国家生物安全认证",
    "href": "http://stock.jrj.com.cn/2021/04/08111732330908.shtml",
    "datetime": "2021-04-08 11:17:09",
    "code": "300601"
  },
  {
    "title": "康泰生物：五联苗是西林瓶装注射用粉末和预填充注射器装注射用混悬液",
    "href": "http://stock.jrj.com.cn/2021/04/07142832324432.shtml",
    "datetime": "2021-04-07 14:28:25",
    "code": "300601"
  },
  {
    "title": "康泰生物：YUAN LI PING 女士将其持有的公司股份 10,000,000 股公司股份转让给其100%控股的合琨公司",
    "href": "http://stock.jrj.com.cn/2021/04/07142432324431.shtml",
    "datetime": "2021-04-07 14:24:36",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：向广东省暨南大学教育发展基金会捐赠3000万元",
    "href": "http://stock.jrj.com.cn/2021/04/02205532272436.shtml",
    "datetime": "2021-04-02 20:55:24",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：发行可转债申请获深交所受理",
    "href": "http://stock.jrj.com.cn/2021/03/24205532210925.shtml",
    "datetime": "2021-03-24 20:55:46",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司研发项目冻干人用狂犬病疫苗采用的细胞是MRC-5株",
    "href": "http://stock.jrj.com.cn/2021/03/17111432150097.shtml",
    "datetime": "2021-03-17 11:14:35",
    "code": "300601"
  },
  {
    "title": "康泰生物“资金饥渴”背后：实控人杜伟民和一众董监高上演减持接力赛",
    "href": "http://stock.jrj.com.cn/2021/03/12172532116847.shtml",
    "datetime": "2021-03-12 17:25:40",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：股东YUAN LI PING拟转让1.46%股份予合琨公司",
    "href": "http://stock.jrj.com.cn/2021/03/11204632110953.shtml",
    "datetime": "2021-03-11 20:46:28",
    "code": "300601"
  },
  {
    "title": "康泰生物跌7.5% 上月初申银万国研报喊买",
    "href": "http://stock.jrj.com.cn/2021/03/09173032098457.shtml",
    "datetime": "2021-03-09 17:30:00",
    "code": "300601"
  },
  {
    "title": "康泰生物跌13.76% 申银万国本月初研报喊买",
    "href": "http://stock.jrj.com.cn/2021/02/18164531987101.shtml",
    "datetime": "2021-02-18 16:45:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：实控人杜伟民拟减持不超200万股",
    "href": "http://stock.jrj.com.cn/2021/02/10202231884637.shtml",
    "datetime": "2021-02-10 20:22:57",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)拟发行不超20亿元可转债 投向百旺信应急工程建设项目和腺病毒载体新冠疫苗车间项目",
    "href": "http://stock.jrj.com.cn/2021/02/08213631872599.shtml",
    "datetime": "2021-02-08 21:36:28",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟发行可转债募资不超20亿元 用于腺病毒载体新冠疫苗车间项目等",
    "href": "http://stock.jrj.com.cn/2021/02/08212931872551.shtml",
    "datetime": "2021-02-08 21:29:18",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：控股股东及其一致行动人持股比例降至49.85%",
    "href": "http://stock.jrj.com.cn/2021/02/04201631850614.shtml",
    "datetime": "2021-02-04 20:16:19",
    "code": "300601"
  },
  {
    "title": "康泰生物腺病毒载体新冠疫苗可试生产",
    "href": "http://stock.jrj.com.cn/2021/02/02152331836910.shtml",
    "datetime": "2021-02-02 15:23:37",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)拟向银行申请不超15.2亿元授信额度",
    "href": "http://stock.jrj.com.cn/2021/01/21201931739540.shtml",
    "datetime": "2021-01-21 20:19:45",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：公司药品生产许可证变更 具备生产新型冠状病毒灭活疫苗(Vero细胞)的基础条件",
    "href": "http://stock.jrj.com.cn/2021/01/11185431671651.shtml",
    "datetime": "2021-01-11 18:54:02",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：监事会主席吕志云累计减持6.7万股 减持数量已过半",
    "href": "http://stock.jrj.com.cn/2021/01/04194131628817.shtml",
    "datetime": "2021-01-04 19:41:25",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司并未收到生产线被征用的通知",
    "href": "http://stock.jrj.com.cn/2020/12/21170731537065.shtml",
    "datetime": "2020-12-21 17:07:43",
    "code": "300601"
  },
  {
    "title": "[康泰生物]康泰生物:五联苗、四联苗(百白破+IPV)获批临床试验 进一步巩固研发领先地位",
    "href": "http://stock.jrj.com.cn/2020/12/14000031516416.shtml",
    "datetime": "2020-12-14 00:00:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：吸附无细胞百白破灭活脊髓灰质炎联合疫苗获批药物临床试验",
    "href": "http://stock.jrj.com.cn/2020/12/11195131466890.shtml",
    "datetime": "2020-12-11 19:51:03",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：股东YUAN LIPING及监事吕志云拟合计减持不超1708.7万股",
    "href": "http://stock.jrj.com.cn/2020/12/09202631451214.shtml",
    "datetime": "2020-12-09 20:26:28",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：4名高管合计减持67.36万股",
    "href": "http://stock.jrj.com.cn/2020/12/09202531451212.shtml",
    "datetime": "2020-12-09 20:25:02",
    "code": "300601"
  },
  {
    "title": "康泰生物：两股东拟减持公司不超2.49%股份",
    "href": "http://stock.jrj.com.cn/2020/12/09202231451193.shtml",
    "datetime": "2020-12-09 20:22:20",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司将继续坚持“以人为本 为民健康”的核心价值观 专注于生物制药领域",
    "href": "http://stock.jrj.com.cn/2020/12/09154531448981.shtml",
    "datetime": "2020-12-09 15:45:44",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司将持续加强营销团队建设和产品学术推广",
    "href": "http://stock.jrj.com.cn/2020/12/09152331448764.shtml",
    "datetime": "2020-12-09 15:23:10",
    "code": "300601"
  },
  {
    "title": "康泰生物：因新型疫苗项目的研发实施 研发费用和管理费用同比增加致使三季度业绩较去年同期相比基本持平",
    "href": "http://stock.jrj.com.cn/2020/12/09083531446211.shtml",
    "datetime": "2020-12-09 08:35:49",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司未来也将考量mRNA疫苗、重组载体疫苗和新型佐剂等新技术路径的应用研究",
    "href": "http://stock.jrj.com.cn/2020/12/08200031442583.shtml",
    "datetime": "2020-12-08 20:00:47",
    "code": "300601"
  },
  {
    "title": "肖恩大侠：从康泰生物、德琪医药、博雅辑因，看中国医药创新的周期与未来 | 集结令第101期",
    "href": "http://stock.jrj.com.cn/2020/12/01150831384663.shtml",
    "datetime": "2020-12-01 15:08:32",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司投资实施的百旺信应急工程建设项目中的车间已完成建设",
    "href": "http://stock.jrj.com.cn/2020/11/19090031313465.shtml",
    "datetime": "2020-11-19 09:00:03",
    "code": "300601"
  },
  {
    "title": "康泰生物2020年前三季度净利4.33亿增长0.58% 投资收益增长",
    "href": "http://stock.jrj.com.cn/2020/11/01140231183663.shtml",
    "datetime": "2020-11-01 14:02:04",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司根据产品研发技术工艺及百旺信应急工程建设项目生产车间规模合理配置产能",
    "href": "http://stock.jrj.com.cn/2020/10/16205631070428.shtml",
    "datetime": "2020-10-16 20:56:44",
    "code": "300601"
  },
  {
    "title": "康泰生物：新冠疫苗生产线可用于重组VSV病毒载体疫苗、手足口病疫苗等病毒类疫苗的生产",
    "href": "http://stock.jrj.com.cn/2020/10/16205631070430.shtml",
    "datetime": "2020-10-16 20:56:32",
    "code": "300601"
  },
  {
    "title": "康泰生物2020年前三季度净利4.15亿—4.5亿 较上年同期基本持平",
    "href": "http://stock.jrj.com.cn/2020/10/16105331066305.shtml",
    "datetime": "2020-10-16 10:53:03",
    "code": "300601"
  },
  {
    "title": "康泰生物：2020年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/10/15230031062789.shtml",
    "datetime": "2020-10-15 23:00:00",
    "code": "300601"
  },
  {
    "title": "[康泰生物]康泰生物:子公司民海生物与江南大学糖类疫苗联合研发中心揭牌成立",
    "href": "http://stock.jrj.com.cn/2020/10/15000031516414.shtml",
    "datetime": "2020-10-15 00:00:00",
    "code": "300601"
  },
  {
    "title": "康泰生物新冠病毒灭活疫苗获批临床试验 君实生物PD-1单抗治疗鼻咽癌3期临床研究达到主要研究终点 |医资日报",
    "href": "http://stock.jrj.com.cn/2020/09/29184730860936.shtml",
    "datetime": "2020-09-29 18:47:57",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：新型冠状病毒灭活疫苗(Vero细胞)获得临床试验批件",
    "href": "http://stock.jrj.com.cn/2020/09/29085330857929.shtml",
    "datetime": "2020-09-29 08:53:56",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)：控股股东及一致行动人持股比例被动稀释至51.14%",
    "href": "http://stock.jrj.com.cn/2020/09/17205230771912.shtml",
    "datetime": "2020-09-17 20:52:09",
    "code": "300601"
  },
  {
    "title": "康泰生物2名股东合计减持42.1万股 套现约7420.55万元",
    "href": "http://stock.jrj.com.cn/2020/09/16193630764104.shtml",
    "datetime": "2020-09-16 19:36:01",
    "code": "300601"
  },
  {
    "title": "千亿康泰生物，刮出了谢谢惠顾？",
    "href": "http://stock.jrj.com.cn/2020/09/09230030713859.shtml",
    "datetime": "2020-09-09 23:00:00",
    "code": "300601"
  },
  {
    "title": "最后冲刺的阿斯利康新冠疫苗按下“暂停键” 康泰生物：个别案例属正常，不影响合作",
    "href": "http://stock.jrj.com.cn/2020/09/09175530712518.shtml",
    "datetime": "2020-09-09 17:55:55",
    "code": "300601"
  },
  {
    "title": "康泰生物回应阿斯利康新冠疫苗暂停试验：出现个别案例属正常现象",
    "href": "http://stock.jrj.com.cn/2020/09/09145530711485.shtml",
    "datetime": "2020-09-09 14:55:00",
    "code": "300601"
  },
  {
    "title": "疫苗股重挫！康泰生物暴跌超16%，合作方新冠疫苗试验暂停！",
    "href": "http://stock.jrj.com.cn/2020/09/09144430711609.shtml",
    "datetime": "2020-09-09 14:44:39",
    "code": "300601"
  },
  {
    "title": "美股风暴来袭！生物疫苗股未能“免疫”……康泰生物最新回应来了！",
    "href": "http://stock.jrj.com.cn/2020/09/09123830710743.shtml",
    "datetime": "2020-09-09 12:38:50",
    "code": "300601"
  },
  {
    "title": "康泰生物回应“阿斯利康暂停新冠疫苗试验”",
    "href": "http://stock.jrj.com.cn/2020/09/09121630710550.shtml",
    "datetime": "2020-09-09 12:16:54",
    "code": "300601"
  },
  {
    "title": "康泰生物独家回应“阿斯利康暂停新冠疫苗试验”：出现个别案例属正常 不影响合作",
    "href": "http://stock.jrj.com.cn/2020/09/09120330710518.shtml",
    "datetime": "2020-09-09 12:03:56",
    "code": "300601"
  },
  {
    "title": "疫苗概念遭遇重挫 康泰生物大跌近19% 万泰生物跌停",
    "href": "http://stock.jrj.com.cn/2020/09/09104830709982.shtml",
    "datetime": "2020-09-09 10:48:00",
    "code": "300601"
  },
  {
    "title": "康泰生物(300601.SZ)大跌超16% 阿斯利康暂停新冠疫苗临床试验",
    "href": "http://stock.jrj.com.cn/2020/09/09095830709763.shtml",
    "datetime": "2020-09-09 09:58:25",
    "code": "300601"
  },
  {
    "title": "[康泰生物]康泰生物获得首个五联疫苗专利证书 填补国内技术空白",
    "href": "http://stock.jrj.com.cn/2020/09/09000031516413.shtml",
    "datetime": "2020-09-09 00:00:00",
    "code": "300601"
  },
  {
    "title": "午间公告：康泰生物获得五联疫苗专利证书",
    "href": "http://stock.jrj.com.cn/2020/09/08122730702725.shtml",
    "datetime": "2020-09-08 12:27:39",
    "code": "300601"
  },
  {
    "title": "9月8日午间公告集锦：康泰生物五联疫苗获专利证书",
    "href": "http://stock.jrj.com.cn/2020/09/08121430702694.shtml",
    "datetime": "2020-09-08 12:14:08",
    "code": "300601"
  },
  {
    "title": "康泰生物与阿斯利康签署《许可协议》 对此前的条款清单进行了详细规定",
    "href": "http://stock.jrj.com.cn/2020/08/21092930555278.shtml",
    "datetime": "2020-08-21 09:29:05",
    "code": "300601"
  },
  {
    "title": "【龙虎榜】康泰生物8月12日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/12180330483725.shtml",
    "datetime": "2020-08-12 18:03:23",
    "code": "300601"
  },
  {
    "title": "【龙虎榜】康泰生物8月7日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/07180430451161.shtml",
    "datetime": "2020-08-07 18:04:13",
    "code": "300601"
  },
  {
    "title": "获阿斯利康新冠疫苗独家授权 康泰生物一字涨停",
    "href": "http://stock.jrj.com.cn/2020/08/07093030447804.shtml",
    "datetime": "2020-08-07 09:30:24",
    "code": "300601"
  },
  {
    "title": "新冠检测试剂获批企业达35家 阿斯利康与康泰生物就新冠疫苗达成合作 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/08/06181630443222.shtml",
    "datetime": "2020-08-06 18:16:16",
    "code": "300601"
  },
  {
    "title": "【龙虎榜】康泰生物8月6日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/06180430443118.shtml",
    "datetime": "2020-08-06 18:04:31",
    "code": "300601"
  },
  {
    "title": "【公告抢先看】晚间重要公告：康泰生物将获阿斯利康腺病毒载体新冠疫苗独家授权、新希望7月生猪销售18.64亿",
    "href": "http://stock.jrj.com.cn/2020/08/06180130443075.shtml",
    "datetime": "2020-08-06 18:01:10",
    "code": "300601"
  },
  {
    "title": "康泰生物：将获阿斯利康腺病毒载体新冠疫苗独家授权",
    "href": "http://stock.jrj.com.cn/2020/08/06173130442878.shtml",
    "datetime": "2020-08-06 17:31:46",
    "code": "300601"
  },
  {
    "title": "康泰生物：二季度恢复增长 在研产品储备丰富",
    "href": "http://stock.jrj.com.cn/2020/08/03083330410239.shtml",
    "datetime": "2020-08-03 08:33:18",
    "code": "300601"
  },
  {
    "title": "康泰生物股东杜兴连减持30万股 套现约6469.8万元",
    "href": "http://stock.jrj.com.cn/2020/07/24210230335822.shtml",
    "datetime": "2020-07-24 21:02:52",
    "code": "300601"
  },
  {
    "title": "康泰生物二季度业绩超去年同期 12个在研项目进入注册程序",
    "href": "http://stock.jrj.com.cn/2020/07/22012030307955.shtml",
    "datetime": "2020-07-22 01:20:02",
    "code": "300601"
  },
  {
    "title": "康泰生物：2020年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/07/11001030208577.shtml",
    "datetime": "2020-07-11 00:10:03",
    "code": "300601"
  },
  {
    "title": "康泰生物：深圳光明基地乙肝疫苗投产",
    "href": "http://stock.jrj.com.cn/2020/06/30213330100498.shtml",
    "datetime": "2020-06-30 21:33:00",
    "code": "300601"
  },
  {
    "title": "康泰生物光明基地乙肝疫苗投产 质量为本持续扩大产能规模",
    "href": "http://stock.jrj.com.cn/2020/06/30173630098794.shtml",
    "datetime": "2020-06-30 17:36:39",
    "code": "300601"
  },
  {
    "title": "康泰生物：乙肝疫苗获药品补充申请批件 批量生产在即",
    "href": "http://stock.jrj.com.cn/2020/06/24121330008392.shtml",
    "datetime": "2020-06-24 12:13:26",
    "code": "300601"
  },
  {
    "title": "康泰生物市值逼近千亿 “疫苗之王”杜伟民跌宕人生引关注",
    "href": "http://stock.jrj.com.cn/2020/06/15075629923520.shtml",
    "datetime": "2020-06-15 07:56:32",
    "code": "300601"
  },
  {
    "title": "康泰生物：努力赶超国际一流 研发全球领先创新疫苗",
    "href": "http://stock.jrj.com.cn/2020/06/12194529910914.shtml",
    "datetime": "2020-06-12 19:45:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：持续加大疫苗技术研发投入 质量管理工作获广泛认可",
    "href": "http://stock.jrj.com.cn/2020/06/12193929910632.shtml",
    "datetime": "2020-06-12 19:39:42",
    "code": "300601"
  },
  {
    "title": "“疫苗皇帝”天价离婚惹争议：外籍前妻分走235亿元 意在转移资产？",
    "href": "http://stock.jrj.com.cn/2020/06/03081329832876.shtml",
    "datetime": "2020-06-03 08:13:50",
    "code": "300601"
  },
  {
    "title": "《基本医疗卫生与健康促进法》今日起实施 康泰生物实控人离婚分割1.6亿股约235亿 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/06/01183329816873.shtml",
    "datetime": "2020-06-01 18:33:10",
    "code": "300601"
  },
  {
    "title": "235亿元！福布斯胡润双料富豪离婚 创A股史上最贵“分手费”",
    "href": "http://stock.jrj.com.cn/2020/05/30171229802267.shtml",
    "datetime": "2020-05-30 17:12:05",
    "code": "300601"
  },
  {
    "title": "235个亿！A股\"最贵离婚\"：乙肝\"疫苗之王\"刷屏！网友：又玩套路？",
    "href": "http://stock.jrj.com.cn/2020/05/30130729801767.shtml",
    "datetime": "2020-05-30 13:07:25",
    "code": "300601"
  },
  {
    "title": "A股再现“天价离婚” 分割市值高达235亿元！涨了33倍的康泰生物后市怎么走",
    "href": "http://stock.jrj.com.cn/2020/05/30115629801570.shtml",
    "datetime": "2020-05-30 11:56:55",
    "code": "300601"
  },
  {
    "title": "A股史上最贵分手费！“疫苗皇帝”离婚 前妻分走价值235亿元股份",
    "href": "http://stock.jrj.com.cn/2020/05/30081029801001.shtml",
    "datetime": "2020-05-30 08:10:40",
    "code": "300601"
  },
  {
    "title": "康泰生物实控人因离婚拟分割公司23.99%股份",
    "href": "http://stock.jrj.com.cn/2020/05/29225329799112.shtml",
    "datetime": "2020-05-29 22:53:13",
    "code": "300601"
  },
  {
    "title": "发行对象认购承诺受关注 康泰生物收深交所问询函",
    "href": "http://stock.jrj.com.cn/2020/05/09170429625688.shtml",
    "datetime": "2020-05-09 17:04:00",
    "code": "300601"
  },
  {
    "title": "康泰生物2020年一季度盈利242.42万 下降97.57% 受新型肺炎疫情影响",
    "href": "http://stock.jrj.com.cn/2020/05/02180929468065.shtml",
    "datetime": "2020-05-02 18:09:26",
    "code": "300601"
  },
  {
    "title": "康泰生物2019年净利5.75亿元 增长31.86% 董事长薪酬125.1万",
    "href": "http://stock.jrj.com.cn/2020/04/30205529434893.shtml",
    "datetime": "2020-04-30 20:55:23",
    "code": "300601"
  },
  {
    "title": "康泰生物2020年第一季度净利242.42万下滑97.57% 疫苗产品销量出现下降",
    "href": "http://stock.jrj.com.cn/2020/04/29153829420037.shtml",
    "datetime": "2020-04-29 15:38:15",
    "code": "300601"
  },
  {
    "title": "康泰生物：吸附无细胞百白破联合疫苗获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/03/31133029157178.shtml",
    "datetime": "2020-03-31 13:30:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/03/26014029109980.shtml",
    "datetime": "2020-03-26 01:40:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：预计一季度净利同比大幅下滑",
    "href": "http://stock.jrj.com.cn/2020/03/25205529108672.shtml",
    "datetime": "2020-03-25 20:55:00",
    "code": "300601"
  },
  {
    "title": "康泰生物2019年净利5.73亿增长32% 生产经营业务有序推进",
    "href": "http://stock.jrj.com.cn/2020/02/29121228919248.shtml",
    "datetime": "2020-02-29 12:12:27",
    "code": "300601"
  },
  {
    "title": "康泰生物3名股东合计减持约24万股 套现约2694万元",
    "href": "http://stock.jrj.com.cn/2020/02/18203828850406.shtml",
    "datetime": "2020-02-18 20:38:57",
    "code": "300601"
  },
  {
    "title": "康泰生物：调整2019年度非公开发行股票方案",
    "href": "http://stock.jrj.com.cn/2020/02/18201928850234.shtml",
    "datetime": "2020-02-18 20:19:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：与艾棣维欣签署《战略合作协议书》 研发新冠DNA疫苗",
    "href": "http://stock.jrj.com.cn/2020/02/09173228798381.shtml",
    "datetime": "2020-02-09 17:32:49",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟与艾棣维欣研发新冠DNA疫苗",
    "href": "http://stock.jrj.com.cn/2020/02/09164928798283.shtml",
    "datetime": "2020-02-09 16:49:00",
    "code": "300601"
  },
  {
    "title": "康泰生物子公司民海生物科技的13价肺炎球菌结合疫苗正式纳入优先审评品种",
    "href": "http://stock.jrj.com.cn/2020/01/20144328705745.shtml",
    "datetime": "2020-01-20 14:43:39",
    "code": "300601"
  },
  {
    "title": "康泰生物：13价肺炎球菌结合疫苗正式纳入优先审评品种",
    "href": "http://stock.jrj.com.cn/2020/01/20140628705563.shtml",
    "datetime": "2020-01-20 14:06:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/09152028650063.shtml",
    "datetime": "2020-01-09 15:20:00",
    "code": "300601"
  },
  {
    "title": "午间公告集锦：凯普生物、康泰生物业绩预增",
    "href": "http://stock.jrj.com.cn/2020/01/09120528649048.shtml",
    "datetime": "2020-01-09 12:05:45",
    "code": "300601"
  },
  {
    "title": "午间公告：康泰生物、凯普生物业绩预增；航锦科技签重要合同",
    "href": "http://stock.jrj.com.cn/2020/01/09120228649047.shtml",
    "datetime": "2020-01-09 12:02:00",
    "code": "300601"
  },
  {
    "title": "康泰生物预计2019年实现盈利5.5亿元至5.9亿元 同比增长26%至35%",
    "href": "http://stock.jrj.com.cn/2020/01/09115828649044.shtml",
    "datetime": "2020-01-09 11:58:51",
    "code": "300601"
  },
  {
    "title": "康泰生物2019年归母净利预增三成左右",
    "href": "http://stock.jrj.com.cn/2020/01/09115528649028.shtml",
    "datetime": "2020-01-09 11:55:03",
    "code": "300601"
  },
  {
    "title": "康泰生物非公开发行股票申请获证监会核准批复",
    "href": "http://stock.jrj.com.cn/2019/12/19191728558886.shtml",
    "datetime": "2019-12-19 19:17:06",
    "code": "300601"
  },
  {
    "title": "康泰生物：13价肺炎球菌结合疫苗申请新药生产注册获受理",
    "href": "http://stock.jrj.com.cn/2019/12/09174528509031.shtml",
    "datetime": "2019-12-09 17:45:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：13价肺炎球菌结合疫苗申请新药生产注册获得受理",
    "href": "http://stock.jrj.com.cn/2019/12/09172728508937.shtml",
    "datetime": "2019-12-09 17:27:55",
    "code": "300601"
  },
  {
    "title": "康泰生物2名股东合计减持131万股 套现约6571万元",
    "href": "http://stock.jrj.com.cn/2019/11/26091928451130.shtml",
    "datetime": "2019-11-26 09:19:34",
    "code": "300601"
  },
  {
    "title": "我武生物、康泰生物跌停 医药股怎么了？",
    "href": "http://stock.jrj.com.cn/hotstock/2019/11/23071728440778.shtml",
    "datetime": "2019-11-23 07:17:15",
    "code": "300601"
  },
  {
    "title": "康泰生物第三季度盈利1.73亿 同比增长92%",
    "href": "http://stock.jrj.com.cn/2019/10/29132328317340.shtml",
    "datetime": "2019-10-29 13:23:33",
    "code": "300601"
  },
  {
    "title": "康泰生物苗向荣登“2019年度挖贝网A股上市公司优秀CFOTop100”",
    "href": "http://stock.jrj.com.cn/2019/10/18152728267707.shtml",
    "datetime": "2019-10-18 15:27:01",
    "code": "300601"
  },
  {
    "title": "前三季度预增仅一成 康泰生物要止步连续5年业绩猛增？",
    "href": "http://stock.jrj.com.cn/2019/10/11084028242008.shtml",
    "datetime": "2019-10-11 08:40:00",
    "code": "300601"
  },
  {
    "title": "前三季度预增仅一成 康泰生物要止步连续5年业绩猛增？",
    "href": "http://stock.jrj.com.cn/2019/10/11084028231431.shtml",
    "datetime": "2019-10-11 08:40:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/10/09215028223716.shtml",
    "datetime": "2019-10-09 21:50:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：前三季度净利同比预增10%-17%",
    "href": "http://stock.jrj.com.cn/2019/10/09200728223354.shtml",
    "datetime": "2019-10-09 20:07:33",
    "code": "300601"
  },
  {
    "title": "康泰生物：前三季度净利预增10%-17%",
    "href": "http://stock.jrj.com.cn/2019/10/09195828223337.shtml",
    "datetime": "2019-10-09 19:58:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：全资子公司民海生物自主研发的23价肺炎球菌多糖疫苗获批签发",
    "href": "http://stock.jrj.com.cn/2019/08/13184127970859.shtml",
    "datetime": "2019-08-13 18:41:05",
    "code": "300601"
  },
  {
    "title": "康泰生物：23价肺炎球菌多糖疫苗获得批签发证明",
    "href": "http://stock.jrj.com.cn/2019/08/13174527970544.shtml",
    "datetime": "2019-08-13 17:45:29",
    "code": "300601"
  },
  {
    "title": "康泰生物2019年上半年盈利2.6亿 积极推进产品的研发",
    "href": "http://stock.jrj.com.cn/2019/08/03083427924965.shtml",
    "datetime": "2019-08-03 08:34:53",
    "code": "300601"
  },
  {
    "title": "康泰生物：上半年净利2.58亿元 同比降9.84%",
    "href": "http://stock.jrj.com.cn/2019/08/02212527922913.shtml",
    "datetime": "2019-08-02 21:25:10",
    "code": "300601"
  },
  {
    "title": "康泰生物2019年上半年净利2.72亿 比上年同期下降5%",
    "href": "http://stock.jrj.com.cn/2019/07/05074627800019.shtml",
    "datetime": "2019-07-05 07:46:24",
    "code": "300601"
  },
  {
    "title": "康泰生物：证监会受理公司非公开发行股票申请",
    "href": "http://stock.jrj.com.cn/2019/06/18170627720492.shtml",
    "datetime": "2019-06-18 17:06:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：子公司完成13价肺炎球菌结合疫苗临床研究阶段工作",
    "href": "http://stock.jrj.com.cn/2019/06/10204527682112.shtml",
    "datetime": "2019-06-10 20:45:20",
    "code": "300601"
  },
  {
    "title": "康泰生物：完成13价肺炎球菌结合疫苗临床研究阶段工作",
    "href": "http://stock.jrj.com.cn/2019/06/10204127682111.shtml",
    "datetime": "2019-06-10 20:41:00",
    "code": "300601"
  },
  {
    "title": "康泰生物抛30亿定增分红7500万 销售费用4年增近24倍",
    "href": "http://stock.jrj.com.cn/2019/05/30075927640147.shtml",
    "datetime": "2019-05-30 07:59:01",
    "code": "300601"
  },
  {
    "title": "康泰生物股东杜伟民增持127万股 耗资6030万元",
    "href": "http://stock.jrj.com.cn/2019/05/22195427608590.shtml",
    "datetime": "2019-05-22 19:54:16",
    "code": "300601"
  },
  {
    "title": "康泰生物拟定增募资不超30亿元加码主业",
    "href": "http://stock.jrj.com.cn/2019/05/15224627575282.shtml",
    "datetime": "2019-05-15 22:46:33",
    "code": "300601"
  },
  {
    "title": "康泰生物拟定增募资不超30亿元",
    "href": "http://stock.jrj.com.cn/2019/05/15221027575178.shtml",
    "datetime": "2019-05-15 22:10:36",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟定增募资不超30亿元",
    "href": "http://stock.jrj.com.cn/2019/05/15212527575063.shtml",
    "datetime": "2019-05-15 21:25:21",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟定增募资不超30亿元 投建疫苗项目",
    "href": "http://stock.jrj.com.cn/2019/05/15212027575057.shtml",
    "datetime": "2019-05-15 21:20:44",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟定增募资不超30亿元 投建疫苗项目",
    "href": "http://stock.jrj.com.cn/2019/05/15212027575055.shtml",
    "datetime": "2019-05-15 21:20:00",
    "code": "300601"
  },
  {
    "title": "康泰生物去年净利4.4亿 同比增长103% 董事长杜伟民薪酬为111万",
    "href": "http://stock.jrj.com.cn/2019/04/27121827496014.shtml",
    "datetime": "2019-04-27 12:18:49",
    "code": "300601"
  },
  {
    "title": "康泰生物：“康泰转债”流通面值低于3000万元 将停止交易",
    "href": "http://stock.jrj.com.cn/2019/04/24192227475921.shtml",
    "datetime": "2019-04-24 19:22:25",
    "code": "300601"
  },
  {
    "title": "康泰生物：吸附无细胞百白破（组分）联合疫苗获临床试验通知书",
    "href": "http://stock.jrj.com.cn/2019/04/16175527407778.shtml",
    "datetime": "2019-04-16 17:55:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：2019年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/03/20234027199180.shtml",
    "datetime": "2019-03-20 23:40:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：一季度净利预降8.99%-22.64%",
    "href": "http://stock.jrj.com.cn/2019/03/20201927198550.shtml",
    "datetime": "2019-03-20 20:19:21",
    "code": "300601"
  },
  {
    "title": "康泰生物：一季度净利预降9%-23%",
    "href": "http://stock.jrj.com.cn/2019/03/20201427198523.shtml",
    "datetime": "2019-03-20 20:14:41",
    "code": "300601"
  },
  {
    "title": "康泰生物2018年利润4.53亿增长111% 乙肝疫苗销量增加",
    "href": "http://stock.jrj.com.cn/2019/02/27094327095875.shtml",
    "datetime": "2019-02-27 09:43:56",
    "code": "300601"
  },
  {
    "title": "康泰生物：已出口部分疫苗成品及原液",
    "href": "http://stock.jrj.com.cn/2019/02/18120227054897.shtml",
    "datetime": "2019-02-18 12:02:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：23价肺炎疫苗预计年中上市销售",
    "href": "http://stock.jrj.com.cn/2019/02/15155427048134.shtml",
    "datetime": "2019-02-15 15:54:00",
    "code": "300601"
  },
  {
    "title": "康泰生物2018年净利最高4.65亿元 同比上升117%",
    "href": "http://stock.jrj.com.cn/2019/01/29110426996045.shtml",
    "datetime": "2019-01-29 11:04:43",
    "code": "300601"
  },
  {
    "title": "康泰生物：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/01/28232026993802.shtml",
    "datetime": "2019-01-28 23:20:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：2018年净利预增98%-117%",
    "href": "http://stock.jrj.com.cn/2019/01/28181426992735.shtml",
    "datetime": "2019-01-28 18:14:00",
    "code": "300601"
  },
  {
    "title": "康泰生物13价肺炎球菌结合疫苗Ⅲ期临床试验数据完成揭盲",
    "href": "http://stock.jrj.com.cn/2019/01/17214426920715.shtml",
    "datetime": "2019-01-17 21:44:05",
    "code": "300601"
  },
  {
    "title": "医药股再度低迷 康泰生物跌近8%",
    "href": "http://stock.jrj.com.cn/2018/12/19104726764089.shtml",
    "datetime": "2018-12-19 10:47:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：预计近两年是公司研发投入高峰期",
    "href": "http://stock.jrj.com.cn/2018/12/06124225462683.shtml",
    "datetime": "2018-12-06 12:42:00",
    "code": "300601"
  },
  {
    "title": "康泰生物签署疫苗研发合作框架协议",
    "href": "http://stock.jrj.com.cn/2018/11/11184425330399.shtml",
    "datetime": "2018-11-11 18:44:27",
    "code": "300601"
  },
  {
    "title": "康泰生物签署疫苗研发合作框架协议 研发新型五联疫苗",
    "href": "http://stock.jrj.com.cn/2018/11/11173925330332.shtml",
    "datetime": "2018-11-11 17:39:43",
    "code": "300601"
  },
  {
    "title": "康泰生物：签署疫苗研发合作框架协议 研发新型五联疫苗",
    "href": "http://stock.jrj.com.cn/2018/11/11171325330290.shtml",
    "datetime": "2018-11-11 17:13:00",
    "code": "300601"
  },
  {
    "title": "康泰生物撤回药品注册申请吃跌停 三季度基金齐撤退",
    "href": "http://stock.jrj.com.cn/2018/11/09133525323083.shtml",
    "datetime": "2018-11-09 13:35:36",
    "code": "300601"
  },
  {
    "title": "史上最牛医药次新股跌回一年前水平 市值蒸发超800亿",
    "href": "http://stock.jrj.com.cn/2018/10/18081225219049.shtml",
    "datetime": "2018-10-18 08:12:23",
    "code": "300601"
  },
  {
    "title": "康泰生物：2018年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/10/12222025197742.shtml",
    "datetime": "2018-10-12 22:20:01",
    "code": "300601"
  },
  {
    "title": "康泰生物三季报净利预增153% 生物疫苗行业几家欢喜几家愁",
    "href": "http://stock.jrj.com.cn/2018/10/12210325197628.shtml",
    "datetime": "2018-10-12 21:03:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：疫苗销售良好 前三季净利预增超139%",
    "href": "http://stock.jrj.com.cn/2018/10/12183525196905.shtml",
    "datetime": "2018-10-12 18:35:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：上半年净利2.9亿元 同比增长306%",
    "href": "http://stock.jrj.com.cn/hotstock/2018/08/29080025017664.shtml",
    "datetime": "2018-08-29 08:00:02",
    "code": "300601"
  },
  {
    "title": "康泰生物半年报净利增逾3倍 乙肝疫苗市占率下滑",
    "href": "http://stock.jrj.com.cn/2018/08/28231125016454.shtml",
    "datetime": "2018-08-28 23:11:00",
    "code": "300601"
  },
  {
    "title": "康泰生物上半年净利润同比增逾3倍",
    "href": "http://stock.jrj.com.cn/2018/08/28211625015761.shtml",
    "datetime": "2018-08-28 21:16:31",
    "code": "300601"
  },
  {
    "title": "康泰生物：上半年净利2.9亿元 同比增逾三倍",
    "href": "http://stock.jrj.com.cn/2018/08/28205025015650.shtml",
    "datetime": "2018-08-28 20:50:00",
    "code": "300601"
  },
  {
    "title": "康泰生物23价肺炎球菌多糖疫苗获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2018/08/22183424987167.shtml",
    "datetime": "2018-08-22 18:34:32",
    "code": "300601"
  },
  {
    "title": "康泰生物：23价肺炎球菌多糖疫苗获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2018/08/22180524987073.shtml",
    "datetime": "2018-08-22 18:05:00",
    "code": "300601"
  },
  {
    "title": "[苏州高新]康泰生物科技、安宇生物科技公司一同到访苏州生命健康小镇",
    "href": "http://stock.jrj.com.cn/2018/08/17000024974876.shtml",
    "datetime": "2018-08-17 00:00:00",
    "code": "300601"
  },
  {
    "title": "午后生物疫苗板块走强 康泰生物再度涨停",
    "href": "http://stock.jrj.com.cn/2018/08/13135524944432.shtml",
    "datetime": "2018-08-13 13:55:59",
    "code": "300601"
  },
  {
    "title": "康泰生物今日跌停 厦门游资系抛售主力",
    "href": "http://stock.jrj.com.cn/2018/08/08164524925045.shtml",
    "datetime": "2018-08-08 16:45:00",
    "code": "300601"
  },
  {
    "title": "康泰生物盘中闪崩",
    "href": "http://stock.jrj.com.cn/2018/08/08101024923156.shtml",
    "datetime": "2018-08-08 10:10:00",
    "code": "300601"
  },
  {
    "title": "康泰生物今日跌停 一机构席位逆市买入",
    "href": "http://stock.jrj.com.cn/2018/08/06165524911444.shtml",
    "datetime": "2018-08-06 16:55:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：董事会换届与其他公司无关",
    "href": "http://stock.jrj.com.cn/2018/08/06162524911338.shtml",
    "datetime": "2018-08-06 16:25:00",
    "code": "300601"
  },
  {
    "title": "康泰生物跳水跌停 成交金额超3亿元",
    "href": "http://stock.jrj.com.cn/2018/08/06110224910051.shtml",
    "datetime": "2018-08-06 11:02:11",
    "code": "300601"
  },
  {
    "title": "康泰生物跳水跌停 成交额近3亿元",
    "href": "http://stock.jrj.com.cn/2018/08/06103424909866.shtml",
    "datetime": "2018-08-06 10:34:41",
    "code": "300601"
  },
  {
    "title": "康泰生物盘中跳水跌停 成交额近3亿元",
    "href": "http://stock.jrj.com.cn/2018/08/06103024909865.shtml",
    "datetime": "2018-08-06 10:30:00",
    "code": "300601"
  },
  {
    "title": "康泰生物：公司狂犬疫苗预计明年上市 尚未正式投产",
    "href": "http://stock.jrj.com.cn/2018/08/06085224909253.shtml",
    "datetime": "2018-08-06 08:52:07",
    "code": "300601"
  },
  {
    "title": "康泰生物：拟增设副董事长职位",
    "href": "http://stock.jrj.com.cn/2018/08/05183524906092.shtml",
    "datetime": "2018-08-05 18:35:00",
    "code": "300601"
  },
  {
    "title": "疫苗股集体反弹 康泰生物涨8%领涨",
    "href": "http://stock.jrj.com.cn/2018/08/02145024895836.shtml",
    "datetime": "2018-08-02 14:50:00",
    "code": "300601"
  }
]